OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 05:48 UTC. Every row links to its source record.

SF3B1 splicing factor 3b subunit 1

ENSG00000115524 · protein coding · Open Targets profile

Component of the 17S U2 SnRNP complex of the spliceosome, a large ribonucleoprotein complex that removes introns from transcribed pre-mRNAs (PubMed:12234937, PubMed:27720643, PubMed:32494006, PubMed:34822310, PubMed:36104565). The 17S U2 SnRNP complex (1) directly participates in early spliceosome assembly and (2) mediates recognition of the intron branch site during pre-mRNA splicing by promoting the selection of the pre-mRNA branch-site adenosine, the nucleophile for the first step of splicing (PubMed:32494006, PubMed:34822310, PubMed:36104565). Within the 17S U2 SnRNP complex, SF3B1 is part of the SF3B subcomplex, which is required for 'A' complex assembly formed by the stable binding of U2 snRNP to the branchpoint sequence in pre-mRNA (PubMed:12234937, PubMed:36104565). Sequence independent binding of SF3A and SF3B subcomplexes upstream of the branch site is essential, it may anchor U2 snRNP to the pre-mRNA (PubMed:12234937). May also be involved in the assembly of the 'E' complex (PubMed:10882114). Also acts as a component of the minor spliceosome, which is involved in the splicing of U12-type introns in pre-mRNAs (PubMed:15146077, PubMed:33509932). Together with other U2 snRNP complex components may also play a role in the selective processing of microRNAs (miRNAs) from the long primary miRNA transcript, pri-miR-17-92 (By similarity). {ECO:0000250|UniProtKB:Q99NB9, ECO:0000269|PubMed:10882114, ECO:0000269|PubMed:12234937, ECO:0000269|PubMed:15146077, ECO:0000269|PubMed:27720643, ECO:0000269|PubMed:32494006, ECO:0000269|PubMed:33509932, ECO:0000269|PubMed:34822310, ECO:0000269|PubMed:36104565}.

In 10 of 15 cancers, the evidence for SF3B1 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751B-cell chronic lymphocytic leukemiaB-cell chronic lymphocytic leukemiaB-cell chronic lymphocytic leukemia: somatic 0.82B-cell chronic lymphocytic leukemia: germline 0.90myelodysplastic syndromemyelodysplastic syndromemyelodysplastic syndrome: somatic 0.61myelodysplastic syndrome: germline 0.78lymphoid leukemialymphoid leukemialymphoid leukemia: germline 0.92myeloproliferative disordermyeloproliferative disordermyeloproliferative disorder: somatic 0.46myeloproliferative disorder: germline 0.76breast adenocarcinomabreast adenocarcinomabreast adenocarcinoma: somatic 0.88leukemialeukemialeukemia: germline 0.80uveal melanomauveal melanomauveal melanoma: somatic 0.61acute myeloid leukemiaacute myeloid leukemiaacute myeloid leukemia: somatic 0.52chronic myeloid leukemiachronic myeloid leukemiachronic myeloid leukemia: somatic 0.53Richter transformationRichter transformationRichter transformation: somatic 0.61rectum malignant melanomarectum malignant melanomarectum malignant melanoma: somatic 0.61vulvar melanomavulvar melanomavulvar melanoma: somatic 0.61mixed cell uveal melanomamixed cell uveal melanomamixed cell uveal melanoma: somatic 0.61carcinoma of liver and intrahepatic bil…carcinoma of liver and intrahepatic biliary tractcarcinoma of liver and intrahepatic biliary tract: somatic 0.61anal melanomaanal melanomaanal melanoma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand
PROTAC
UniProt Ubiquitination, Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.07801400125026703 (upper bound 0.12639999389648438). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of SF3B1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of SF3B1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.